Skip to main content

Advertisement

Log in

ASO Visual Abstract: Long-Term Postsurgical Outcomes of Neoadjuvant Chemoradiation (CROSS) Versus Chemotherapy (FLOT) for Multimodal Treatment of Adenocarcinoma of the Esophagus and the Esophagogastric Junction

  • ASO Visual Abstract
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Funding

No sources of funding were used to assist in the preparation of this work.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Patrick S. Plum MD.

Ethics declarations

Hans Fuchs has received an educational grant from Intuitive Surgical (ESOMAP trial); is a member of the Advisory Board for Activ Surgical, Medtronic, Stryker, and Distal Motion; and holds stock options in Fortimedix Surgical. Florian Gebauer, Patrick S. Plum, Alexander Damanakis, Seung-Hun Chon, Felix Popp, Thomas Zander, Alexander Quaas, Thomas Schmidt, Wolfgang Schröder, and Christiane J. Bruns have no conflicts of interest to declare.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gebauer, F., Plum, P.S., Damanakis, A. et al. ASO Visual Abstract: Long-Term Postsurgical Outcomes of Neoadjuvant Chemoradiation (CROSS) Versus Chemotherapy (FLOT) for Multimodal Treatment of Adenocarcinoma of the Esophagus and the Esophagogastric Junction. Ann Surg Oncol 30, 7513–7514 (2023). https://doi.org/10.1245/s10434-023-13822-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-023-13822-8

Navigation